Ciclesonide for the treatment of airway hyperresponsiveness

Study identifier:BY9010/CH-101

ClinicalTrials.gov identifier:NCT00826969

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Ciclesonide for the treatment of airway hyperresponsiveness. The Mannitol-Asthma-Ciclesonide Study (MACS). A double-blind, randomized, parallel group study.

Medical condition

asthma

Phase

Phase 4

Healthy volunteers

Study drug

Ciclesonide, Placebo

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 70 Years

Date

Study Start Date: 01 Sept 2008

Primary Completion Date: 01 Jul 2010

Study Completion Date: 01 Oct 2011

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2016 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Location

Nycomed

Basel, Switzerland, 4031

Arms	Assigned Interventions
Active Comparator: 1 Ciclesonide 320µg	Drug: Ciclesonide 320µg Ciclesonide versus Placebo
Placebo Comparator: 2 Placebo	Drug: Placebo Placebo

"There is no result for the study"

Documents available

BY9010-CH-101-RDS-2012-10-29.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Investigators

Principal Investigator

AstraZeneca AstraZeneca

AstraZeneca